Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM3 | Q86V86 | 4/20 | 1.00 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 3/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 3/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 3/20 | 1.00 |
| ▸ | PIM1 | P11309 | 3/20 | 1.00 |
| ▸ | GSK3A | P49840 | 2/20 | 1.00 |
| ▸ | GSK3B | P49841 | 2/20 | 1.00 |
| ▸ | PRKACA | P17612 | 2/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 1.00 |
| ▸ | CDK8 | P49336 | 2/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 2/20 | 1.00 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 2/20 | 1.00 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.47 |
| ▸ | CLK2 | P49760 | 2/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.47 |
| ▸ | CDC7 | O00311 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL460818 | 0.70 | DAPK3 (0.54) | PIM3CLK4DAPK3PRKD3DYRK1A | |
| SCHEMBL17292789 | 0.70 | DAPK3 (0.54) | PIM3CLK4DAPK3PRKD3DYRK1A | |
| SCHEMBL4207656 | 0.68 | PARP1 (0.54) | PIM3CLK4DAPK3PRKD3DYRK1A | |
| SCHEMBL7227346 | 0.66 | PDPK1 (0.51) | PIM3CLK4DAPK3PRKD3DYRK1A | |
| SCHEMBL273173 | 0.66 | CHRM4 (0.57) | PIM3CLK4DAPK3PRKD3DYRK1A | |
| SCHEMBL18666379 | 0.65 | HPGD (0.53) | PIM3CLK4DAPK3PRKD3DYRK1A | |
| SCHEMBL10565373 | 0.62 | PIM1 (0.57) | PIM3CLK4DAPK3PRKD3DYRK1A | |
| SCHEMBL358129 | 0.62 | PDPK1 (1.00) | PIM3CLK4DAPK3PRKD3DYRK1A | |
| SCHEMBL8237434 | 0.61 | GRM1 (0.54) | PDPK1KDM4EHPGDALDH1A1KMT2A | |
| SCHEMBL7221584 | 0.61 | PDPK1 (0.48) | PIM3CLK4DAPK3PRKD3DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | ABBOTT LABORATORIES (US) | 2009-01-29 | — | — | US | claimed |
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | ABBOTT LABORATORIES (US) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | PIM1, PIM3, PIM2 | PIM3 2/4885CLK4 792/4885DAPK3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.